2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 13 August 2019Portfolio NewsDeciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
12 August 2019Portfolio NewsDDF notes AstronauTx secures £6.5 million Financing with Investment from DDF
8 August 2019Portfolio NewsLilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia
7 August 2019Portfolio NewsQ&A with Pulmocide CEO Garth Rapeport – Why Pulmocide is developing targeted lung therapy.
22 July 2019Portfolio NewsWashington Regional and Urgent Team Family of Urgent Care Join Forces- 17 July 2019Portfolio NewsKarus Therapeutics Strengthens Clinical Leadership Team with Appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer
8 July 2019Portfolio NewsDDF notes MedaRed Raises $6.5 Million Financing with Investment from DDF
2 July 2019SV NewsDDF notes the appointment of Jonathan Behr, PhD as Partner
29 June 2019SV NewsHow to spot the hidden gem investment funds- 29 May 2019Portfolio NewsTiaki Therapeutics, a DDF-formed company, announces collaboration with Eisai
28 May 2019Portfolio NewsCardioFocus Raises $55M in Financing- 28 May 2019Portfolio NewsCardioFocus lands $55M in funding for product launches
